Biotie Therapies - Decisions of extraordinary general meeting

Resolutions of the Extraordinary General Meeting of Biotie Therapies Corp.

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 29 OCTOBER 2009 at
11.00 a.m.

Resolutions of the Extraordinary General Meeting of Biotie Therapies
Corp.

The Extraordinary General Meeting of Biotie Therapies Corp. was held
on 29 October 2009. The Meeting resolved to approve all proposals.

The Board of Directors

The number of the members of the Board of Directors was resolved to
be eight and Dr Peter Fellner was elected as a new member of the
Board of Directors.

Amendment to the Articles of Association

The Extraordinary General Meeting resolved to amend, due to the
amendment to the Finnish Companies Act, the method and minimum period
for publishing the summons to the general meetings in the Article 10
of the company's Articles of Association. After the amendment the
Article 10 reads as follows:"10 § Summons to the meetings
The shareholders of the company are summoned to the shareholders'
meeting by publishing the summons on the company's website. The
summons shall be published not earlier than two (2) months before the
last registration date mentioned in the summons and not later than
three (3) weeks prior to the date of the meeting. In addition, the
Board of Directors shall publish a summary notice of the
shareholders' meeting in one or more national daily newspaper, or by
sending the notice of the shareholders' meeting as a registered
letter or other verifiable way to the shareholders' address, which is
registered in the share register."

Authorisation of the Board of Directors to decide on an issuance of
shares as well as the issuance of options and other special rights
entitling to shares

The Extraordinary General Meeting authorised the Board of Directors
to resolve on one or more issues which contains the right to issue
new shares or dispose of the shares in the possession of the company
and to issue options or other specific rights to the shares pursuant
to chapter 10 of the Companies Act. The authorisation consists of up
to 72,000,000 shares in the aggregate.

The authorisation does not exclude the Board of Directors' right to
decide on a directed issue. The authorisation may be used for
material arrangements from the company's point of view, such as
financing or implementing business arrangements or investments or for
other such purposes determined by the Board of Directors in which
case a weighty financial reason for issuing shares, options or other
specific rights and possibly directing a share issue exists. The
authorisation cannot, however, be used to create new share-based
incentive schemes.

The Board of Directors was authorised to resolve on all other terms
and conditions of a share issue, options and other specific share
entitlements as referred to in chapter 10 of the Companies Act,
including the payment period, determination grounds for the
subscription price and subscription price or allocation of shares,
option rights or specific rights free of charge or that the
subscription price may be paid besides in cash also by other assets
either partially or entirely.

The authorisation is effective until 30 June 2010 and it supersedes
earlier authorisations.

The minutes of the meeting will be available on the company's website
as from 12 November 2009.

Turku, 29 October 2009

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:
Timo Veromaa, President and CEO, Biotie Therapies Corp.
tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com

www.biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media